SC
MSLE

Steven Cohen’s Satellos Bioscience MSLE Stock Holding History

Steven Cohen’s Portfolio MSLE Stock Details MSLE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.31M Sell
682,700
-8,078
-1% -$55.5K 0.01% 1712
2026
Q1 		$3.89M Buy
+690,778
New +$6.79M 0.01% 1873

Other funds holding MSLE

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Steven Cohen's MSLE Position: Q2 2026 in Review

Steven Cohen reduced its Satellos Bioscience (MSLE) stake by 1.2% in Q2 2026, selling an estimated $55.5K and leaving 682,700 shares worth $5.31M. The position accounts for 0.01% of the portfolio, ranked #1712.

Steven Cohen first reported a position in MSLE in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold MSLE as of Q2 2026.

  • Steven Cohen held 682,700 shares of Satellos Bioscience worth $5.31M as of Q2 2026.
  • Steven Cohen sold 8,078 Satellos Bioscience shares in Q2 2026, an estimated $55.5K.
  • Satellos Bioscience made up 0.01% of Steven Cohen's portfolio in Q2 2026, its #1712 holding.
  • Steven Cohen first reported a position in Satellos Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Satellos Bioscience as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.